Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
830 stopped studies mapped to Genitourinary System Carcinoma and descendants · 90% state a reason
Over the 830 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00285415 | A Phase II Evaluation of Docetaxel and Carboplatin Followed by Tumor Volume Directed… | Phase 2 | terminated | Feb 2, 2006 | Carilion Clinic | Investigator abruptly left Carilion. | Investigator |
| NCT03741712 | A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC | Phase 1 / Phase 2 | terminated | Nov 15, 2018 | Jiangsu HengRui Medicine Co., Ltd. | According to the available data from the trial，the sponsor determined to terminate this study. | Other (stated, no rule matched) |
| NCT03514836 | A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic… | Phase 1 / Phase 2 | terminated | May 2, 2018 | SOTIO a.s. | insufficient accrual | Enrollment / accrual |
| NCT02698176 | A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced… | Phase 1 | terminated | Mar 3, 2016 | Merck Sharp & Dohme LLC | This study was terminated due to limited efficacy and not due to safety reasons. | Safety / toxicity |
| NCT02495103 | Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney… | Phase 1 / Phase 2 | terminated | Jul 13, 2015 | National Cancer Institute (NCI) | Vandetanib is no longer available as Sanofi has decided not to provide additional drug. All… | Other (stated, no rule matched) |
| NCT02844582 | Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant… | Phase 2 | terminated | Jul 26, 2016 | University of California, Davis | Poor accrual of subjects onto study | Enrollment / accrual |
| NCT04585932 | Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the… | Phase 2 | withdrawn | Oct 14, 2020 | M.D. Anderson Cancer Center | At the request of the ad interim Department Chairman due to PI is no longer at institution. | Other (stated, no rule matched) |
| NCT03327662 | Utilising CTC Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer(CTC-STOP) | Phase 3 | terminated | Oct 31, 2017 | Institute of Cancer Research, United Kingdom | Underrecruitment | Other (stated, no rule matched) |
| NCT02853162 | Ablative tReatment of Inoperable REnal Cell Carcinoma Using STereotactic Body…(ARREST) | Phase 2 | terminated | Aug 2, 2016 | UMC Utrecht | Slow inclusion | Other (stated, no rule matched) |
| NCT04609800 | Study on the Utilization of Cabozantinib in Adult Patients With Advanced or Metastatic…(CAROLINE) | — | withdrawn | Oct 30, 2020 | Ipsen | Unfavorable opinion of IRB/IEC | Other (stated, no rule matched) |
| NCT03563352 | Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in… | — | withdrawn | Jun 20, 2018 | University of Southern California | Zero accrual | Enrollment / accrual |
| NCT02947152 | HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma | Phase 1 | terminated | Oct 27, 2016 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT02131376 | Investigating a Novel Modifiable Factor Affecting Renal Function After Partial… | N/A | terminated | May 6, 2014 | Indiana University | slow accrual, interim analysis showed no statistical significance | Efficacy / futility |
| NCT02071719 | Prediction of Response to Kinase Inhibitors Based on Protein Phosphorylation Profiles in… | — | terminated | Feb 26, 2014 | M. Labots | not stated | Not stated |
| NCT04262375 | A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer…(DOMINATION) | Phase 2 | withdrawn | Feb 10, 2020 | University Health Network, Toronto | Overall clinical activity (ORR) for oleclumab + durvalumab is minimal across tumor types and does… | Other (stated, no rule matched) |
| NCT04399824 | Focal Radiation Therapy for the Treatment of Low or Intermediate-Risk Prostate Cancer | N/A | withdrawn | May 22, 2020 | Jonsson Comprehensive Cancer Center | Study did not open | Other (stated, no rule matched) |
| NCT01673386 | A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With…(TAURUS) | Phase 2 | terminated | Aug 28, 2012 | AVEO Pharmaceuticals, Inc. | Sponsor | Other (stated, no rule matched) |
| NCT02595918 | Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery | Phase 1 | terminated | Nov 4, 2015 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT01806064 | Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal… | Phase 1 / Phase 2 | terminated | Mar 7, 2013 | Tracon Pharmaceuticals Inc. | The study did not meet endpoint. | Other (stated, no rule matched) |
| NCT03570476 | Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer | Phase 2 | terminated | Jun 27, 2018 | University of Washington | Terminated due to slow accrual | Enrollment / accrual |
| NCT03957096 | A Safety Study of SGN-CD47M in Patients With Solid Tumors | Phase 1 | terminated | May 21, 2019 | Seagen Inc. | Sponsor decision based on portfolio prioritization | Sponsor / business decision |
| NCT01939028 | Lymph Node Mapping in Patients With Newly Diagnosed Endometrial Cancer Undergoing Surgery | N/A | terminated | Sep 11, 2013 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT03719300 | Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC | Phase 2 | terminated | Oct 25, 2018 | Anchiano Therapeutics Israel Ltd. | Lack of efficacy | Efficacy / futility |
| NCT03598816 | PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for…(PIVOT-RCC) | Phase 2 | withdrawn | Jul 26, 2018 | Washington University School of Medicine | FDA Contingencies unresolved | Other (stated, no rule matched) |
| NCT04260360 | Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma | Phase 1 | withdrawn | Feb 7, 2020 | NanOlogy, LLC | Not initiated | Other (stated, no rule matched) |
| NCT03167151 | Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)(PemBla) | Phase 1 / Phase 2 | terminated | May 25, 2017 | University of Oxford | The study failed to recruit within the permitted timeframe | Enrollment / accrual |
| NCT01249443 | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors… | Phase 1 | terminated | Nov 29, 2010 | AIDS Malignancy Consortium | Inadequate accrual rate | Enrollment / accrual |
| NCT01859689 | Internal Radiation Therapy in Treating Patients With Low-Risk Prostate Cancer | Phase 2 | withdrawn | May 22, 2013 | Jonsson Comprehensive Cancer Center | no participants enrolled | Enrollment / accrual |
| NCT02597894 | Targeted Biopsies in Determining Response in Patients With Prostate Cancer Undergoing… | N/A | withdrawn | Nov 5, 2015 | Jonsson Comprehensive Cancer Center | P. I. left the Institution. Study never opened | Other (stated, no rule matched) |
| NCT02688348 | Quality of Life After Bladder-Preservation Chemotherapy and Radiation Therapy in Patients… | N/A | withdrawn | Feb 23, 2016 | Jonsson Comprehensive Cancer Center | not stated | Not stated |
| NCT02168062 | Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and… | Phase 2 | terminated | Jun 20, 2014 | University of California, San Francisco | Funding | Funding |
| NCT03596710 | Image-Guided Biopsies in Identifying Mechanisms of Resistance in Participants With… | N/A | withdrawn | Jul 24, 2018 | Jonsson Comprehensive Cancer Center | sponsor withdrew study | Other (stated, no rule matched) |
| NCT02212730 | A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell… | Phase 1 | terminated | Aug 8, 2014 | Merck Sharp & Dohme LLC | Terminated early due to low enrollment | Enrollment / accrual |
| NCT03407976 | Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies(APPEASE) | Phase 1 | terminated | Jan 23, 2018 | University of Utah | Funding source withdrew financial support prior to start of Phase II portion of study | Funding |
| NCT02169284 | Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery | Phase 2 | terminated | Jun 23, 2014 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02170389 | Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer | N/A | terminated | Jun 23, 2014 | Roswell Park Cancer Institute | sponsor having financial difficulties | Funding |
| NCT00953446 | Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of… | N/A | terminated | Aug 6, 2009 | Beth Israel Deaconess Medical Center | not stated | Not stated |
| NCT02089334 | Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal… | Phase 1 / Phase 2 | terminated | Mar 17, 2014 | Rexahn Pharmaceuticals, Inc. | not stated | Not stated |
| NCT03827473 | Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone…(ACADEMIC) | Phase 2 | terminated | Feb 1, 2019 | University of Utah | The trial was closed because the changing standard of care landscape, making this trial not… | Other (stated, no rule matched) |
| NCT03343613 | A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid… | Phase 1 | terminated | Nov 17, 2017 | Eli Lilly and Company | Study terminated due to strategic business decision by Eli Lilly and Company. | Sponsor / business decision |
| NCT02837991 | A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell… | Phase 1 | terminated | Jul 20, 2016 | Celldex Therapeutics | Development of CDX-014 discontinued | Other (stated, no rule matched) |
| NCT03517995 | Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention | Phase 2 | withdrawn | May 8, 2018 | H. Lee Moffitt Cancer Center and Research Institute | Grant not approved | Other (stated, no rule matched) |
| NCT03927248 | PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer | Phase 1 / Phase 2 | withdrawn | Apr 25, 2019 | HealthPartners Institute | funding issues | Funding |
| NCT01312376 | Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer | Phase 1 | terminated | Mar 10, 2011 | Abramson Cancer Center at Penn Medicine | not stated | Not stated |
| NCT03335059 | Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced…(RITE-USA) | Phase 3 | terminated | Nov 7, 2017 | Medical Enterprises Ltd. | poor enrollment | Enrollment / accrual |
| NCT02541903 | Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma | Phase 2 | terminated | Sep 4, 2015 | University of Alabama at Birmingham | poor overall accrual | Enrollment / accrual |
| NCT03137758 | A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the… | Phase 1 | terminated | May 3, 2017 | Pellficure Pharmaceuticals, Inc | Reformulation of study drug to help reduce the pill burden as higher doses are evaluated. | Other (stated, no rule matched) |
| NCT02487849 | HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive…(HIPEC) | Phase 2 | withdrawn | Jul 2, 2015 | Krankenhaus Barmherzige Schwestern Linz | actually limited personnel ressources | Other (stated, no rule matched) |
| NCT00854022 | Genetic Susceptibility to Kidney Cancer | — | terminated | Mar 2, 2009 | Baylor College of Medicine | Funding ended | Funding |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | Phase 2 | terminated | Jul 12, 2011 | Cambridge University Hospitals NHS Foundation Trust | Following DMC review, due to slow recruitment of evaluable patients. | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Feb 5, 2021source: clinicaltrials